Japan Biosimilars- Landscape Today Outlook Tomorrow
US$ 4,500.00
“Biosame” entry, uninterrupted supply and companies’ strong front-end footprint requirement makes it distinctAfter a decade, JP Biosimilar guideline’s first revision expected in FY2020 –Demonstrate Ch...
January 2020
156 pages
BIOCON, Growth Drivers - Long Term and Uncertain, Expenses - Near Term and Certain
US$ 140.00
Q3FY13 result of Biocon was moderately better than our estimates. Revenue of ... in Simvastatin. As per the company, biosimilars seem to be the biggest growth drivers in the longer term; however we do not see any visibility as of ... unreported licensing income) at 1x. We retain our Market Perform rating on Biocon.
December 2017
7 pages
Pain Management- New Discoveries and Treatment Options in Abuse Deterrent Era
US$ 3,500.00
... management of pain. Late stage NCE pipeline drugs (Cebranopadol, Mirogabalin, NKT-181, AVP-923,…) and Novel technologies targeting formulation change in old generic drugs (ORB-201, OX-51, ARX-04,CL-108, once daily Pregabalin..) for pain management has potential to reduce opioids ...
August 2016
135 pages
India Pharma Outlook 2016: Milestones to Watch – Growth from Exports and Domestic Getting Better, Implementation of Policies under “Make-in-India”, Overture of A New Ministry
US$ 1,500.00
... Lupin, Cipla, Sun pharma) and sustainable growth from Domestic formulation (e.g. Alkem, Cipla, Sun pharma, Dr Reddy), mainly from Chronic diseases’ segment, due to growth ... explore further opportunities of growth, Indian pharma companies have started developing complex generics/biosimilars. Almost all companies ...
March 2016
35 pages
Buccal Drug Delivery Systems: Opportunities and Challenges in Buccal, Sublingual Films, Tablets & Sprays – Detailed Analysis on Technologies and Pipeline Development
US$ 3,000.00
... as Biodelivery Sciences, Bioalliance pharma (Onexo), Meda pharma, Orexo, Generex, Teijin are actively involved in developing oral mucoadhesive buccal delivery systems while sublingual technology have been used by Teva, Sun pharma, Grunenthal, Neurax, Angelini, Sandoz, Ethypharm, Arrow generics, Purdue and ...
October 2015
70 pages
New Phase of Mab biosimilar knocks the door Biosimilar Opportunities In Japan
US$ 4,000.00
... players (Daiichi-Sankyo, KHK), JP Innovator+ GE companies (Meiji, Fujifilm, Nippon Kayaku, Mochida, and Kissei), Global Multinationals (Pfizer, Sandoz) and some rising star JP local companies (Yoshindo, Gene Techno Science, Sanwa Kagaku ...
January 2015
65 pages
Therapeutic Class Overview: New avatars of microbes super bugs a growing threat worldwide
US$ 1,500.00
... infections during the treatment were not available. If that fails, the gains ... super infections” warranting need for new classes of antibiotics and other preventive/therapeutic approaches ... Gram Negative infections and CRE. Pipeline of novel targets being used to develop new drugs to treat infections and resistance ...
February 2014
12 pages
Global Pharmaceutical and Biotechnology Outlook 2014 - Japan Pharma
US$ 2,500.00
... : NHI price cut, Japan generic opportunity, Prograf, Xtandi, Isavuconazole, Myrbetriq, Astellas, Chugai, Actemra, Perjeta, biosimilar, Kadcyla, breast cancer, prostate cancer, MPDL3280A, Daiichi Sankyo, Edoxaban , Ranbaxy, Dainnipon Sumitomo, Dainnipon, cancer stem cell inhibitor, BBI-608, Latuda, DS-3025 ...
January 2014
141 pages
TAKEDA , Challenges Ahead for its New European Presiden
US$ 500.00
... failure a moderate Positive- while development of Brexpiprazole looks a close competitor!.........Vedolizumab (MLN0002, UR, US/EU, vedolizumab, α4β7 integrin inhibitor, Ulcerative colitis / Crohn’s disease) and MLN-9708 (PhIII, Multiple Myeloma) are the most promising late ...
January 2014
24 pages
Global Pharmaceutical & Biotechnology Outlook 2014: Major US and EU
US$ 2,500.00
... melanoma and breast cancer from major pharmaceutical companies. Many of them are ... high premium in speculation of getting acquired (ex. Roche-Alexion). Going forward, Economies of Scale will ... repurchase program and dividend policy. Global Biopharmaceutical Outlook 2014-Global Pharma, released by MP Advisors ...
January 2014
113 pages
Global Pharmaceutical & Biotechnology Outlook 2014: Mature Biotech
US$ 2,500.00
... : Acorda, Alexion, Amgen, Biogen Idec, Celgene, Gilead, Regeneron, Vertex, ACOR, ALXN, AMGN, BIIB, CELG, GILD, REGN, VRTX, Soliris, Eculizumab, Asfotase alfa, Onyx, Kyprolis, RRMM, Denosumab, Prolia, XGEVA, Enbrel, Neupogen/ Neulasta, Biosimilar, Ampyra, Multiple Sclerosis, TECFIDERA, BG-12, PLEGRIDY, Gazyva ...
January 2014
145 pages
Enanta- It is just the beginning of good news
US$ 90.00
... SVR12 data of SAPPHIRE-I –oral regimen (ENTA’s /ABT-450 boosted Abbvie’s ritonavir, ... data from the first of six Phase III HCV trial of ENTA/AbbVie's using its oral IFN free regimen. ... 1) and regulatory filing in 2nd half of 2014 we expect ENTA shares to appreciate further. We are positive on the PhIII study ...
November 2013
2 pages
Regeneron - Eylea’s Growth Potential and Pipeline is Lucrative Enough!
US$ 140.00
... of Eylea (aflibercept, VEGF-Trap Eye, L, wet-AMD, Central Retinal Vein Occlusion – CRVO, partnered with Bayer for ex-US) in Diabetic Macular Edema (DME) and myopic choroidal neovascularization (mCNV) and promise of the late-stage pipeline esp. anti-PCSK9 mAb, Alirocumab (REGN727, PhIII, Hypercholesterolemia ...
October 2013
7 pages
Therapy Class Overview : Hepatitis C Virus Infection
US$ 1,000.00
... Oral IFN –Free combinations for Treatment of HCV and ROW opportunity Competitive Landscape - IFN-Free drugs HCV Vaccines and their progress Difficult to treat and drugs for HCV-HIV co infection Market ...
October 2013
33 pages
Therapy Class Overview: Rituximab biosimilar
US$ 2,000.00
... emerging market experience in India and Mexico. Rituximab biosililar pipeline, and the current status of clinical development What are the Innovator's strategy in protecting rituximab franchise? Competition to biosimilar rituximab ...
October 2013
45 pages
ABLYNX - Nanobodies - Turnarond on the Horizon!
US$ 140.00
... of ALX-0061 (PhI/II, Anti-IL6R, RA) with AbbVie under attractive terms (deal value of $840m/~€630m) and news flow in last one year brought back Ablynx (ABLX ... ) and its nanobody platform’s’ potential in the limelight! Though ABLX suffered from several setbacks in 2011, ...
October 2013
7 pages
Incyte- INCB39110 – Another JAK-Fruit in INCY’s Basket
US$ 140.00
... RA – Xeljanz) and in light of current competition in plaque psoriasis market. For more detail, please read our report on INCY, released on Oct. 3, 2013, titled, 'INCB39110 – Another JAK-Fruit in INCY ...
October 2013
5 pages
Merck Update: HCV combo, Lambrolizumab and Corporate Restructuring Program
US$ 90.00
Merck announced restructuring (cost efficiency) program which is likely to ... by 2015) announced by the Company through workforce reduction across all functional divisions, head quarter relocation, out ... . More focused attention on therapy areas where Merck has proven its abilities irrespective of unmet need ...
October 2013
3 pages
MEDIVIR - Simeprevir- Good with and without IFN Combinations!
US$ 140.00
... Simeprevir/IFN/RBV combination (TMC435, once daily Protease Inhibitor, PI, R, HCV, partnered with Tibotec/JNJ) in Japan and progress in IFN free combinations with various drugs has helped Medivir ... Though Gilead’s Sofosbuvir/IFN/RBV is not far behind, the real competition is for IFN free combinations and MVIR ...
September 2013
3 pages